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A B S T R A C T
Background: The left ventricular reverse remodeling (LVRR) in idiopathic dilated cardiomyopathy (DCM)
and the treatment with carvedilol in infants with severe heart failure remain poorly understood.
Methods: We reviewed the medical records of 5 infants around 12 months old referred to our hospital
with severe heart failure due to DCM. Increased left ventricular fractional shortening (LVFS) by more
than 10% and the percent of normal of left ventricular end-diastolic dimension (%LVDd) less than 120%
were deﬁned as LVRR in this study.
Results: DCM onset ranged from 8 to 16 months. Initial treatment of their acute heart failure was
successful in all 5 but 4 patients relapsed despite the usual dose of carvedilol (induction 0.02–
maintenance 0.4 mg/kg/day), and developed worsening heart failure. Brain natriuretic peptide (BNP)
levels which increased again after the acute treatment had fallen subsequent to discontinuing or
decreasing carvedilol. Over 24 months, LVFS had increased from 11  2% (mean  SD) to 34  5%
(p < 0.05), and %LVDd decreased from 149  27% to 108  11% (p < 0.05).
Conclusions: LVRR was found at 2 years after the onset of DCM. Usual dose induction of carvedilol
therapy can sometimes worsen heart failure after successful initial conventional treatment for the acute
heart failure in DCM. Close control of carvedilol treatment may determine the prognosis of infantile DCM
around 12 months old. It is prudent to increase low-dose carvedilol slowly corresponding with the BNP
level.
 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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The prognosis in individual children with idiopathic dilated
cardiomyopathy (DCM) is unpredictable ranging from death to
intractable heart failure to occasional spontaneous recovery
[1,2]. Unfortunately, there is no marker for the prognosis of
DCM. Everitt et al. reported a series of children of whom 22%
recovered normal left ventricular function and size; 51% had died
or undergone heart transplantation, and 27% had persistently
abnormal echocardiograms 2 years post acute onset [3]. They
reported that younger age and lower left ventricular end-diastolic
dimensions were the best indicators for improvement. Grifﬁn et al.
documented that the prognosis in DCM <2 years of age at onset
was better than at onset >2 years [4]. The cause and prognosis of* Corresponding author at: Department of Pediatrics, National Cardiovascular
Center, 5-7-1 Fujishirodai, Suita-shi, Osaka 565-8565, Japan. Tel.: +81 6 6833 5012;
fax: +81 6 6872 7486.
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0914-5087/ 2015 Published by Elsevier Ltd on behalf of Japanese College of CardioloDCM are diverse, and its characteristics appear to differ depending
on the age at the onset. On the other hand, anti-heart failure
therapies with established efﬁcacy in adults appear to have a
limited impact on pediatric outcomes [5–9]. We report the clinical
course and the pitfalls of carvedilol treatment in patients who
presented with infantile DCM around 12 months of age.
Methods
We retrospectively reviewed the clinical course and left
ventricular reverse remodeling (LVRR) from the medical records
of ﬁve infants aged around 12 months referred to our hospital
between 2006 and 2013 with DCM. There were three boys and two
girls. The onset of DCM ranged from 8 to 16 months, median
13 months. In this study, the time of the initial admission was
regarded as the onset of DCM. The left ventricular end-diastolic
dimension (LVDd) and the left ventricular fractional shortening
(LVFS) in two-dimensional echocardiograms (2-DE) during the
clinical course were analyzed. The changes in brain natriuretic
peptide (BNP) levels were also tabulated in all ﬁve patients. LVDdgy.
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LVDd = log BSA  31.4 + 40.2). Furthermore, we documented
changes in mitral regurgitation (MR) in 2-DE and T waves in V6
in 12-lead electrocardiogram. An increase of LVFS more than 10%
and %LVDd less than 120% were deﬁned as LVRR for this study. We
investigated LVFS and %LVDd in the 4 points based on the time
after the onset. The timing of the 4 points was (1) onset, (2)
6 months, (3) 12 months, and (4) 24 months.
The mean values are shown as mean  1 standard deviation.
After repeated measure ANOVA was performed, Tukey’s honesty
signiﬁcant difference test was used for differences between groups.
Differences were considered statistically signiﬁcant at p < 0.05.
Results
Outline of clinical course and the treatment of heart failure
The presentation at the onset of DCM was as follows.
Gastrointestinal symptoms including vomiting and diarrhea were
the most frequent and occurred in 3 patients (patients 2, 4, 5). Poor
feeding and failure to thrive for a few months before the onset
occurred in 3 patients (patients 3, 4, 5). Dyspnea and cardiogenic
shock occurred in 2 patients (patients 1, 4). Chest X-ray showed
cardiomegaly in all ﬁve. Mean cardiothoracic ratio in the chest X-
ray was 62% in 5 patients, and a low LVFS (mean  SD, 11  2%) and
a dilated LVDd 41.0  7.1 (149  27% of normal) were detected by
2DE. The degree of MR in 2-DE were as follows: moderate 2 patients
(patients 1, 3) and slight 3 patients (patients 2, 4, 5). Creatine
phosphokinase was not elevated. All patients had been diagnosed as
having DCM. No perfusion defects were found in 99mTc myocardial
perfusion imaging in any patient. Negative T waves in V6 in the 12-
lead electrocardiograms were present in two patients (patients 1, 5)
and ﬂat T waves were seen in three patients (patients 2, 3, 4).
All ﬁve patients, responded to conventional therapy for acute
heart failure using catecholamines and phosphodiesterase (PDE) III
inhibitor. Oral medicines given after treating acute heart failure
were as follows. Digoxin, 0.01 mg/kg/day, furosemide and
spironolactone, 3–4 mg/kg/day, and enalapril, 0.1–0.2 mg/kg were
administered at some stage in all ﬁve patients (Table 1). All ﬁve
patients had carvedilol therapy. Four patients experiencedTable 1
Treatment in acute and late period.
Patient 1 2 
Gender Male Female 
Age at onset (months) 9 16 
Acute treatment
Duration
MRS (days) 99 
DOA (days) 191 116 
DOB (days) 222 169 
PDE III inhibitor (days) 287 193 
Others hANP Furosemide 
Furosemide 
Late period
Oral medication (mg/kg)
Digoxin 0.01 ! off 0.01 
Furosemide 3 ! off 3 ! off 
Spironolactone 3 ! off 3 ! off 
Trichlormethiazide 
Pimobendan 0.005 ! off 0.01 ! off 
Enalapril 0.1 ! off 0.1 
Carvedilol (max) mg/kg 0.1 0.14 
Carvedilol (maintenance) 0.05 0.05 
MRS, mechanical respiratory support; DOA, dopamine; DOB, dobutamine; PDE III in
ECMO, extracorporeal membrane oxygenation; CHDF, continuous hemodialysis ﬁltraworsening heart failure after the administration of carvedilol.
Four patients (the exception being patient 1) were referred to our
hospital as heart transplantation candidates, because of intractable
heart failure. The carvedilol was stopped in one patient (patient 2),
decreased in one patient (patient 3), and decreased and
discontinued in two patients (patients 4, 5). The re-induction
dose of carvedilol was 0.02 mg/kg/day in the 3 patients, started
when BNP had decreased to less than 400 pg/ml. The maintenance
dose of carvedilol was 0.05 mg-0.20 mg/kg/day 1 year after the
onset of DCM. Mean cardiothoracic ratio in the chest X-ray was 52%
in ﬁve patients, and mean LVFS and mean %LVDd measured by
2-DE were 26  12% and 121  16% of normal, respectively. Twenty-
four months after the onset of DCM, mean LVFS and mean %LVDd
detected by 2-DE were 34  5% and 108  11% of normal. MR had
improved for 2 years in four patients. Slight MR was present only in
patient 3. T waves in V6 in the 12-lead electrocardiograms were
positive in four patients the exception was patient 4. New York Heart
Association class was I in all ﬁve patients.
Brief histories
Patient 1
A nine-month old boy was referred to our hospital because of
pallor and dyspnea after bathing. He had undergone mechanical
respiratory ventilation under deep sedation for 3 months (Fig. 1).
Four months after the onset of DCM, enalapril and digoxin were
administered, and subsequently carvedilol (0.003 mg/kg/day) was
started 8 months after the onset. His LVFS increased 10 months
after the onset of DCM. Thirty-seven months after the onset of DCM
his indices were improved to 96% of normal and 39%, respectively.
A ZASP (a Z-band alternatively spliced PDZ motif-containing
protein) mutation was detected. He had developmental delay
because of neurological disease.
Patient 2
A 16-month-old girl developed pallor and vomiting. Acute heart
failure initially improved with catecholamine and PDE III inhibitor
but subsequently worsened and her BNP increased dramatically,
after discontinuing positive inotropic agents and starting carve-
dilol (0.025 mg/kg/day) at 16 days (Fig. 2). Subsequently she3 4 5
Male Female Male
8 13 15
50
7
7 359 1
10 387 19
Furosemide hANP Furosemide
Furosemide
ECMO, CHDF
0.01 0.01 0.01
4.5 ! off 3 ! 2 4
3.4 ! off 3 ! 2 4
0.01 ! 0.005
0.01 0.01
0.2 0.1 0.2
0.35 0.47 0.15
0.2 0.09 0.06
hibitor, phosphodiesterase III inhibitor; hANP, human atrial natriuretic peptide;
tion.
Fig. 1. Changes in BNP with the dose of carvedilol and parameters in two-
dimensional echocardiograms of patient 1. BNP, brain natriuretic peptide; LVFS, left
ventricular fractional shortening; %LVDd, percent of normal left ventricular end-
diastolic dimension.
Fig. 3. Changes in BNP with the dose of carvedilol and parameters in two-
dimensional echocardiograms of patient 3. BNP, brain natriuretic peptide; LVFS, left
ventricular fractional shortening; %LVDd, percent of normal left ventricular end-
diastolic dimension.
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had been increased to 0.14 mg/kg/day for two weeks. BNP
decreased after discontinuing carvedilol. Digoxin and enalapril
were started. She was referred to our hospital for heart
transplantation. Dopamine (DOA), dobutamine (DOB), and PDE
III inhibitor were stopped at 116 days, 169 days, and 193 days,
respectively. Her LVFS increased 4 months after the onset of DCM.
Carvedilol at 0.02 mg/kg/day was re-started 5 months after the
onset. Her LVDd and her LVFS, with carvedilol, 0.05 mg/kg/day,
24 months after the onset of DCM were improved to 107% of
normal and 37%, respectively.
Patient 3
An 8-month-old boy had poor feeding, vomiting, and dyspnea.
DOA, DOB, and PDE III inhibitor were stopped at 7 days, 7 days, and
10 days, respectively. Carvedilol, 0.1 mg/kg/day was started at
16 days and then increased to 0.35 mg/kg/day for four weeks. His
low activity and poor feeding recurred and BNP increased from
299 pg/ml to 451 pg/ml (Fig. 3). He was referred to our outpatient
clinic. BNP decreased after decrease of carvedilol. LVFS was 114% ofFig. 2. Changes in BNP with the dose of carvedilol and parameters in two-
dimensional echocardiograms of patient 2. BNP, brain natriuretic peptide; LVFS, left
ventricular fractional shortening; %LVDd, percent of normal left ventricular end-
diastolic dimension.normal and 33%, on a dose of carvedilol of 0.20 mg/kg/day,
24 months after the onset.
Patient 4
A 13-month-old girl had cardiogenic shock. She had undergone
extracorporeal membrane oxygenation for 3 days and mechanical
respiratory ventilation for 15 days. After discontinuing positive
inotropic agents, carvedilol (0.06 mg/kg/day) was started in the
second week. Carvedilol was increased to 0.47 mg/kg/day for
2 months. BNP decreased to 817 pg/ml at 3 months after the onset,
but 4 months after the onset it had increased to 3030 pg/ml. BNP
changes with the dose of carvedilol are shown in Fig. 4. DOB and
PDE III inhibitor were administered. She developed a cerebral
infarction 5 months after the onset of DCM and had undergone
respiratory mechanical support for 47 days because of chronic
heart failure. She was referred to our hospital for heart
transplantation because of a low LVFS. Her BNP decreased in
conjunction with weaning her carvedilol dosage. When her BNP
decreased to less than 100 pg/ml, carvedilol was re-started at
0.02 mg/kg/day. Thirty-three months after the onset of DCM, herFig. 4. Changes in BNP with the dose of carvedilol and parameters in two-
dimensional echocardiograms of patient 4. BNP, brain natriuretic peptide; LVFS, left
ventricular fractional shortening; %LVDd, percent of normal left ventricular end-
diastolic dimension.
Fig. 5. Changes in chest X-ray, M-mode in two dimensional echocardiogram and 12-lead electrocardiogram in patient 4. (Left) 7 months after the onset of DCM. Cardiothoracic
ratio 68%, fractional shortening 7%, left ventricular end-diastolic dimension 44.2 mm, ﬂat T wave in V6. (Right) 33 months after the onset of DCM. Cardiothoracic ratio 52%,
fractional shortening 35%, left ventricular end-diastolic dimension 29.4 mm, positive T wave in V6.
Fig. 6. Changes in BNP with the dose of carvedilol and parameters in two-
dimensional echocardiograms of patient 5. BNP, brain natriuretic peptide; LVFS, left
ventricular fractional shortening; %LVDd, percent of normal left ventricular end-
diastolic dimension.
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(Fig. 5). Her BNP was 9 pg/ml with carvedilol of 0.09 mg/kg/day.
Patient 5
A 15-month-old boy had diarrhea and vomiting. The left
ventricular end diastolic pressure was 27 mmHg by cardiac
catheterization on the 12th day of illness. PDE III inhibitor was
stopped on the16th day. Carvedilol was started at 15 days at
0.05 mg/kg/day. His BNP was increased to 3278 pg/ml, when the
dose of carvedilol was 0.15 mg/kg/day on the 26th day. He was
referred to our hospital. BNP decreased after decreasing the dose of
carvedilol. When his BNP was less than 400 pg/ml, carvedilol was
re-started at 0.02 mg/kg/day (Fig. 6). Twenty-six months after the
onset with the dose of 0.06 mg/kg/day, his LVFS had increased from
9% to 35%, and his LVDd decreased from 173% to 114% of normal.
His BNP was 14 pg/ml.
Changes in BNP
Changes in BNP with the carvedilol dose in each patient are
shown (Figs. 1–4 and 6). Although BNP initially decreased after
administration of catecholamines and PDE III inhibitors, it
increased again in 4/5 patients after starting carvedilol. Patient
1 was the exception. BNP decreased after discontinuing carvedilol
in patient 2, and decreased after decreasing carvedilol in patients 3,
4, and 5. BNP was decreased to below 200 pg/ml, 3 months after the
onset in 3 patients (patients 1, 2, 3). It was decreased at 6 months
after the onset of DCM in patients 4 and 5.
Changes in 2-DE and electrocardiogram
Changes in LVDd and LVFS by 2-DE are shown in Figs. 1–4. LVFS
had increased gradually for 6 months in all patients except # 4. On
the other hand, LVDd in the 4 patients had decreased at the same
time after the onset of DCM. The percent of normal LVDd wasdecreased from 1 to 2 years after the onset of DCM. LVFS and
%LVDd in the 4 points based on time after onset are shown in
Fig. 7. LVDd at each time interval was: 1, 41.0  7.1 mm; 2,
39.4  4.7 mm; 3, 35.1  4.9 mm; 4, 34.2  4.0 mm. LVFS at 12 and
24 months after the onset were signiﬁcantly higher than at the onset
(p < 0.05). LVFS at 24 months after the onset was also signiﬁcantly
higher than that at 6 months post-onset (p < 0.05). The percent of
LVDd at 12 and 24 months after the onset were signiﬁcantly lower
than those at the onset (p < 0.05). The percent of LVDd at 24 months
after the onset was also signiﬁcantly lower than that at 6 months after
the onset (p < 0.05). The left ventricular function improved and LVRR
Fig. 7. The left ventricular parameters in two-dimensional echocardiograms based
on the time after the onset of disease. LVFS, left ventricular fractional shortening,
%LVDd, percent of normal left ventricular end-diastolic dimension.
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electrocardiogram changed with LVRR.
Changes in body weight in the respective patients are shown in
Figs. 1–4. The body weight of Patient 2 increased 4 months after the
onset of DCM, and the body weight in other patients increased
more than 6 months after the onset. The individual times are as
follows: (1) onset, 8.2  1.0 kg; (2) 6 months, 7.9  1.1 kg; (3)
12 months, 9.4  1.0 kg; (4) 24 months, 11.7  1.2 kg. The body
weights at 24 months were signiﬁcantly larger than those at the
previous three time points (p < 0.05).
Discussion
Reverse remodeling of the left ventricle continues for about
2 years after the onset of infantile DCM, if the optimal treatment for
acute and chronic heart failure is administered [10]. In our small
series, BNP decreased to less than 200 pg/ml within the ﬁrst 2–3
months after the onset with optimal treatment of acute heart
failure. Subsequently, LVFS improved and LVDd decreased during
the ﬁrst 6 months. After that, body weight increased for the next
6 months. LVFS and %LVDd percent of normal reached close to
normal values over 1 year. With optimal treatment, the outcome in
some patients with infantile DCM developing around 12 months
will be good. Unfortunately, there is no marker for the prognosis of
DCM.
It is unknown whether low-maintenance dose carvedilol also
improves left ventricular function. LVFS had improved slightly
before re-induction of carvedilol. An important question is
whether these infants presenting with severe heart failure around
their ﬁrst birthday represent a single disease of ‘‘infantile benign
DCM which the onset of disease is around 12 months and can
develop LVRR by treatment’’ or not. A diagnosis of typical acute
myocarditis is rare around 12 months [11]. ‘‘Infantile benign
DCM’’ may be a unique form of myocarditis speciﬁc to this age
group, which slowly resolves under supportive care with low-
dose catecholamines for several months. On the other hand,
remarkable improvement of the left ventricular function may
occur because of its characteristic of the younger age. Therefore,
the use of carvedilol immediately after successful treatment of
acute heart failure must be handled carefully to avoid worsening
heart failure.
Treatment for acute severe heart failure due to DCM has
recently been more successful due to the addition of PDE III
inhibitors and human atrial natriuretic peptides to our conven-
tional therapies. However, worsening heart failure often coincides
with the introduction of the beta-blocker carvedilol immediatelyafter the initial acute treatment. Beta-blockers have a negative
inotropic effect which may depress cardiac function, consequently
inappropriate introduction of carvedilol may worsen heart failure,
even if given in so called ‘‘low-dose’’, 0.01–0.02 mg/kg/day.
Especially notable were the BNP levels in patient 4 which
decreased remarkably with a decrease of carvedilol. Failure to
decrease carvedilol for re-worsening of heart failure may precipi-
tate cardiac shock and be fatal for the patient (example patient 4).
It is questionable whether ‘‘the belief that the more the dose of
beta-blockers, the better the outcome’’ [12]. With this attitude
when faced with increasing heart failure physicians are tempted to
increase the carvedilol dosage resulting in some patients
developing intractable heart failure and the need for heart
transplantation. This dichotomy of response is a major pitfall for
the unwary. Although carvedilol is accepted as useful in the
treatment of DCM, it is important to consider its potential negative
effects and to use beta-blockers according to the changes in BNP
levels which reﬂect the degree of heart failure.
The timing for heart transplantation in a child with DCM is
critical. Premature transplantation in a child who is destined to
lead a relatively normal existence for a number of years presents
risks and costs that are unnecessary and unacceptable. Some
infants can avoid heart transplantation at these ages by the
optimal treatment. However, the optimal treatment was not only
uniform, but also various depending on each patient in many
points. The patients in poor condition are often infectious, and it
furthermore worsens their heart failure and general conditions.
Although it is most important to stabilize their condition, rapid
increase in carvedilol dose which is not suitable for their condition
must be avoided. It is essential that low and slow induction of
carvedilol corresponding with their condition is used, because
this is critical.
Assessment of ‘‘too much or too little’’ carvedilol based on
clinical ﬁndings alone is extremely difﬁcult and we would urge the
use of change in BNP as a valuable factor in judging what to do. The
BNP level is also a good guide when starting and adjusting beta-
blocker therapy in patients with low left ventricular ejection
fraction [13]. Starting beta-blockers might be avoided when BNP is
more than 400–500 pg/ml. Guided by the BNP, the dose of beta-
blocker should be gradually increased in patients with severe heart
failure. An over-dose and urgent increase in the dose of beta-
blockers in severe heart failure does not necessarily bring good
results. Because an acceptable-dose on a given patient is unknown,
the very low-dose of beta-blockers should be the safest choice. One
of the problems relating to prognosis of infantile DCM may be the
early initiation of carvedilol. If low-dose carvedilol is not tolerated
by patients with severe heart failure, introduction of very low dose
carvedilol less than 0.01 mg/kg/day, should be tried [14,15].
On the other hand, it was reported that 9% of patients with
normal left ventricular function and size within 2 years of
diagnosis later underwent heart transplantation or died [3]. Longer
follow-up after normalization is indispensable as heart transplan-
tation can recur. Further investigation of ‘‘infantile DCM’’ is
needed.
Conclusion
LVRR in infantile DCM developing around 12 months can occur
for 2 years with the optimal treatment. Usual carvedilol therapy
can sometimes worsen heart failure after successful initial
conventional treatment for the acute heart failure in DCM. Careful
treatment guided by BNP levels must be done with recognition of
the potentially negative inotropic effects of beta-blockers in this
population. Carvedilol therapy with very low-dose and slow
induction is safe.
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